Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b trial of ruxolitinib cream in adults with moderate atopic dermatitis
NL-OMON59567Phase 3Completed
- Sponsor
- Incyte
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Ruxolitinib cream with Vehicle control (2 arms). Primary endpoints: EASI75 at Week 8 and IGA treatment success at Week 8. Started Sep 2024; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON59567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59567.